Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$229.57
2.701.19%
al cierre: -
$229.89
0.320.14%
After hour: Oct 17, 5:26 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
AbbVie Inc ha un obiettivo di prezzo di consenso pari a $227.84, stabilito in base alle ultime valutazioni degli analisti di 28. Le ultime 3 valutazioni degli analisti sono state rilasciate da Raymond James, Piper Sandler y B of A Securities il octubre 17, 2025, octubre 10, 2025 y octubre 3, 2025. Con un obiettivo di prezzo medio di $261.67 tra le Raymond James, Piper Sandler y B of A Securities, c'è un implicito 13.82% upside per AbbVie Inc da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
Raymond James
Piper Sandler
B of A Securities
Evercore ISI Group
Berenberg
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para AbbVie
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/17/2025 | 8.75% | Raymond James | $236 → $250 | Reiterates | Outperform → Outperform | |||
10/10/2025 | 23.54% | Piper Sandler | $231 → $284 | Maintains | Overweight | |||
10/03/2025 | 9.18% | B of A Securities | $220 → $251 | Maintains | Neutral | |||
10/01/2025 | — | HSBC | — | Downgrade | Buy → Hold | |||
09/22/2025 | -3.43% | Evercore ISI Group | $207 → $222 | Maintains | Outperform | |||
09/17/2025 | 17.45% | Berenberg | $170 → $270 | Upgrade | Hold → Buy | |||
09/16/2025 | 2.22% | JP Morgan | $200 → $235 | Maintains | Overweight | |||
09/15/2025 | 6.57% | Cantor Fitzgerald | $215 → $245 | Maintains | Overweight | |||
09/12/2025 | 13.1% | Wells Fargo | $240 → $260 | Maintains | Overweight | |||
09/12/2025 | 4.4% | BMO Capital | $215 → $240 | Maintains | Outperform | |||
08/12/2025 | 0.48% | Piper Sandler | → $231 | Assumes | → Overweight | |||
08/01/2025 | -9.96% | Evercore ISI Group | $205 → $207 | Maintains | Outperform | |||
08/01/2025 | -1.26% | Guggenheim | $216 → $227 | Maintains | Buy | |||
08/01/2025 | 10.92% | Morgan Stanley | $250 → $255 | Maintains | Overweight | |||
08/01/2025 | 2.66% | Raymond James | $227 → $236 | Maintains | Outperform | |||
05/14/2025 | -10.83% | Citigroup | $210 → $205 | Downgrade | Buy → Neutral | |||
04/29/2025 | -6.04% | Guggenheim | $214 → $216 | Maintains | Buy | |||
04/28/2025 | -11.26% | B of A Securities | $200 → $204 | Maintains | Neutral | |||
04/28/2025 | -1.26% | Raymond James | $220 → $227 | Maintains | Outperform | |||
04/28/2025 | -10.83% | Evercore ISI Group | $204 → $205 | Maintains | Outperform | |||
04/28/2025 | 8.75% | Morgan Stanley | $241 → $250 | Maintains | Overweight | |||
04/22/2025 | -8.65% | Cantor Fitzgerald | → $210 | Initiates | → Overweight | |||
04/21/2025 | -13% | B of A Securities | $223 → $200 | Maintains | Neutral | |||
04/17/2025 | -6.91% | Guggenheim | $214 → $214 | Reiterates | Buy → Buy | |||
04/11/2025 | -8.65% | Citigroup | $215 → $210 | Maintains | Buy | |||
04/09/2025 | 4.83% | Morgan Stanley | $239 → $241 | Maintains | Overweight | |||
04/08/2025 | -15.61% | Goldman Sachs | → $194 | Assumes | → Neutral | |||
03/05/2025 | 4.4% | Wells Fargo | $210 → $240 | Maintains | Overweight | |||
03/04/2025 | -3% | B of A Securities | $200 → $223 | Maintains | Neutral | |||
02/03/2025 | -6.48% | Citigroup | $205 → $215 | Maintains | Buy | |||
02/03/2025 | -5.61% | Truist Securities | $211 → $217 | Maintains | Buy | |||
02/03/2025 | -17.35% | UBS | $181 → $190 | Maintains | Neutral | |||
02/03/2025 | -8.65% | Wells Fargo | $195 → $210 | Maintains | Overweight | |||
02/03/2025 | 3.96% | Morgan Stanley | $224 → $239 | Maintains | Overweight | |||
02/03/2025 | -4.3% | Raymond James | $218 → $220 | Reiterates | Outperform → Outperform | |||
02/03/2025 | -6.91% | Guggenheim | $212 → $214 | Maintains | Buy | |||
02/03/2025 | -6.48% | BMO Capital | $208 → $215 | Maintains | Outperform | |||
01/28/2025 | -10.83% | Citigroup | $215 → $205 | Maintains | Buy | |||
01/27/2025 | -1.26% | Piper Sandler | $220 → $227 | Maintains | Overweight | |||
01/17/2025 | -7.78% | Guggenheim | $221 → $212 | Maintains | Buy | |||
01/08/2025 | -8.22% | Truist Securities | $215 → $211 | Maintains | Buy | |||
12/17/2024 | -4.3% | Piper Sandler | $212 → $220 | Maintains | Overweight | |||
12/10/2024 | -16.92% | B of A Securities | → $191 | Reinstates | → Neutral | |||
11/22/2024 | -10.39% | Leerink Partners | → $206 | Upgrade | Market Perform → Outperform | |||
11/18/2024 | -15.18% | Wells Fargo | $205 → $195 | Maintains | Overweight | |||
11/15/2024 | -10.83% | Wolfe Research | → $205 | Initiates | → Outperform | |||
11/13/2024 | -13% | JP Morgan | $210 → $200 | Maintains | Overweight | |||
11/12/2024 | -21.27% | UBS | $200 → $181 | Maintains | Neutral | |||
11/12/2024 | -6.48% | Citigroup | $226 → $215 | Maintains | Buy | |||
11/12/2024 | -9.52% | BMO Capital | $228 → $208 | Maintains | Outperform | |||
11/12/2024 | -2.56% | Morgan Stanley | $231 → $224 | Maintains | Overweight | |||
11/06/2024 | -3.87% | Guggenheim | $212 → $221 | Maintains | Buy | |||
11/04/2024 | — | Argus Research | — | Upgrade | Hold → Buy | |||
10/31/2024 | 4.4% | Cantor Fitzgerald | $200 → $240 | Maintains | Overweight | |||
10/31/2024 | -8.65% | B of A Securities | $195 → $210 | Maintains | Neutral | |||
10/31/2024 | -0.82% | BMO Capital | $220 → $228 | Maintains | Outperform | |||
10/31/2024 | -1.69% | Citigroup | $215 → $226 | Maintains | Buy | |||
10/31/2024 | -13% | UBS | $195 → $200 | Maintains | Neutral | |||
10/31/2024 | 0.48% | Morgan Stanley | $218 → $231 | Maintains | Overweight | |||
10/25/2024 | -6.48% | Citigroup | $170 → $215 | Maintains | Buy | |||
10/18/2024 | -15.18% | B of A Securities | $185 → $195 | Maintains | Neutral | |||
10/17/2024 | -4.3% | BMO Capital | $214 → $220 | Maintains | Outperform | |||
10/17/2024 | -11.7% | Bernstein | → $203 | Initiates | → Market Perform | |||
10/10/2024 | -6.48% | Truist Securities | $210 → $215 | Maintains | Buy | |||
10/09/2024 | -15.18% | UBS | $185 → $195 | Maintains | Neutral | |||
10/07/2024 | -7.78% | Barclays | $200 → $212 | Maintains | Overweight | |||
10/07/2024 | -2.13% | TD Cowen | $195 → $225 | Maintains | Buy | |||
08/23/2024 | -9.09% | Piper Sandler | $196 → $209 | Maintains | Overweight | |||
08/12/2024 | -5.17% | Morgan Stanley | $211 → $218 | Maintains | Overweight | |||
08/05/2024 | -13% | Cantor Fitzgerald | $200 → $200 | Reiterates | Overweight → Overweight | |||
07/26/2024 | -19.53% | UBS | $172 → $185 | Maintains | Neutral | |||
07/26/2024 | -13% | Cantor Fitzgerald | $200 → $200 | Reiterates | Overweight → Overweight | |||
07/26/2024 | -8.65% | Truist Securities | $195 → $210 | Reiterates | Buy → Buy | |||
07/26/2024 | -10.83% | Wells Fargo | $200 → $205 | Maintains | Overweight | |||
07/26/2024 | -13% | Barclays | $187 → $200 | Maintains | Overweight | |||
07/25/2024 | -8.65% | JP Morgan | $190 → $210 | Maintains | Overweight | |||
07/19/2024 | -6.91% | BMO Capital | $180 → $214 | Maintains | Outperform | |||
07/11/2024 | -14.74% | Morgan Stanley | $191 → $196 | Maintains | Overweight | |||
07/09/2024 | -13% | Cantor Fitzgerald | $200 → $200 | Reiterates | Overweight → Overweight | |||
07/02/2024 | -17.35% | Piper Sandler | $190 → $190 | Maintains | Overweight | |||
06/20/2024 | -13% | Cantor Fitzgerald | $200 → $200 | Reiterates | Overweight → Overweight | |||
06/18/2024 | -17.35% | Piper Sandler | $185 → $190 | Maintains | Overweight | |||
06/05/2024 | -19.53% | HSBC | → $185 | Upgrade | Hold → Buy | |||
05/17/2024 | -13% | Cantor Fitzgerald | → $200 | Initiates | → Overweight | |||
04/29/2024 | -16.92% | Morgan Stanley | $196 → $191 | Maintains | Overweight | |||
04/29/2024 | -18.66% | Barclays | $195 → $187 | Maintains | Overweight | |||
04/29/2024 | -21.7% | BMO Capital | $195 → $180 | Maintains | Outperform | |||
03/27/2024 | -15.18% | Barclays | $185 → $195 | Maintains | Overweight | |||
03/22/2024 | -17.35% | Guggenheim | $188 → $190 | Maintains | Buy | |||
02/06/2024 | -25.18% | UBS | $165 → $172 | Maintains | Neutral | |||
02/06/2024 | -17.79% | Raymond James | $181 → $189 | Maintains | Outperform | |||
02/06/2024 | -15.18% | Truist Securities | $180 → $195 | Maintains | Buy | |||
02/05/2024 | -13% | Wells Fargo | $180 → $200 | Maintains | Overweight | |||
02/05/2024 | -17.79% | Raymond James | $181 → $189 | Maintains | Outperform | |||
02/05/2024 | -15.18% | BMO Capital | $187 → $195 | Maintains | Outperform | |||
02/05/2024 | -19.53% | Barclays | $175 → $185 | Maintains | Overweight | |||
01/29/2024 | — | William Blair | — | Upgrade | Market Perform → Outperform | |||
01/23/2024 | -23.88% | Barclays | $170 → $175 | Maintains | Overweight | |||
01/02/2024 | -21.7% | Wells Fargo | $195 → $180 | Maintains | Overweight | |||
12/18/2023 | -32.14% | HSBC | $167 → $156 | Downgrade | Buy → Hold |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de AbbVie (ABBV)?
El último precio objetivo de AbbVie (NYSE:ABBV) fue comunicado por Raymond James el octubre 17, 2025. La firma de analistas fijó un precio objetivo para $250.00 que espera ABBV a rise dentro de 12 meses (un posible 8.75% upside). 60 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre AbbVie (ABBV)?
La última calificación de analistas para AbbVie (NYSE:ABBV) fue proporcionada por Raymond James, y AbbVie reiterado su outperform calificación.
¿Cuándo se produjo la última revisión al alza de AbbVie (ABBV)?
La última revisión al alza de AbbVie Inc se produjo en septiembre 17, 2025, cuando Berenberg elevó su precio objetivo a $270. Berenberg anteriormente tenía a hold para AbbVie Inc.
¿Cuándo fue la última revisión a la baja de AbbVie (ABBV)?
La última revisión a la baja de AbbVie Inc se produjo en octubre 1, 2025, cuando HSBC cambió su precio objetivo de N/A a N/A para AbbVie Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para AbbVie (ABBV)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de AbbVie, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de AbbVie se registró el octubre 17, 2025, por lo que la próxima calificación estará disponible en torno al octubre 17, 2026.
¿Es correcta la calificación de los analistas sobre AbbVie (ABBV)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de AbbVie (ABBV) fue un reiterado con un precio objetivo de $236.00 a $250.00. El precio actual al que cotiza AbbVie (ABBV) es de $229.89, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.